Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376641384> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W4376641384 endingPage "104019" @default.
- W4376641384 startingPage "104019" @default.
- W4376641384 abstract "Six ALK TKIs (crizotinib, ceritinib, alectinib, brigatinib, lorlatinib, ensartinib) have received first-line treatment indication of advanced ALK+ NSCLC in various countries. In Ba/F3 cells, lorlatinib achieved lowest IC50 among these 6 ALK TKIs against EML4-ALK variant 1 or 3. In 2022, 7 abstracts reported updated efficacy and safety data from CROWN. With a median follow-up time of 36.7 months, the 3-year progression-free survival (PFS) rate was 63.5% for lorlatinib-treated patients and the median PFS of lorlatinib still has not been reached. Importantly, post-lorlatinib treatment median PFS2 was 74.0% at 3-years. Lorlatinib-treated Asian patients achieved similar 3-year PFS rate as overall lorlatinib-treated patients. Median PFS was 33.3 months among lorlatinib-treated EML4-ALK v3 patients. CNS AE occurred fewer than 1 event per patient over the median follow-up time of 36.7 months and most resolved without intervention. Altogether these data affirm our belief that lorlatinib should be the treatment of choice of advanced ALK+ NSCLC." @default.
- W4376641384 created "2023-05-17" @default.
- W4376641384 creator A5007345070 @default.
- W4376641384 creator A5060083195 @default.
- W4376641384 creator A5087923582 @default.
- W4376641384 date "2023-07-01" @default.
- W4376641384 modified "2023-10-05" @default.
- W4376641384 title "From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC" @default.
- W4376641384 cites W2055402151 @default.
- W4376641384 cites W2099530756 @default.
- W4376641384 cites W2168691181 @default.
- W4376641384 cites W2592529118 @default.
- W4376641384 cites W2624310346 @default.
- W4376641384 cites W2726054049 @default.
- W4376641384 cites W2784414491 @default.
- W4376641384 cites W2804764624 @default.
- W4376641384 cites W2842842413 @default.
- W4376641384 cites W2890523839 @default.
- W4376641384 cites W2894476389 @default.
- W4376641384 cites W2908470444 @default.
- W4376641384 cites W2908885437 @default.
- W4376641384 cites W2922836343 @default.
- W4376641384 cites W2925139051 @default.
- W4376641384 cites W2969431490 @default.
- W4376641384 cites W3007475361 @default.
- W4376641384 cites W3022131485 @default.
- W4376641384 cites W3048441995 @default.
- W4376641384 cites W3101089668 @default.
- W4376641384 cites W3130459803 @default.
- W4376641384 cites W3147630494 @default.
- W4376641384 cites W3157110935 @default.
- W4376641384 cites W3168056273 @default.
- W4376641384 cites W3169719877 @default.
- W4376641384 cites W3190602458 @default.
- W4376641384 cites W3200994971 @default.
- W4376641384 cites W4220865515 @default.
- W4376641384 cites W4220866365 @default.
- W4376641384 cites W4281289792 @default.
- W4376641384 cites W4281390999 @default.
- W4376641384 cites W4281683594 @default.
- W4376641384 cites W4281873496 @default.
- W4376641384 cites W4311691578 @default.
- W4376641384 cites W4319333462 @default.
- W4376641384 doi "https://doi.org/10.1016/j.critrevonc.2023.104019" @default.
- W4376641384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37187318" @default.
- W4376641384 hasPublicationYear "2023" @default.
- W4376641384 type Work @default.
- W4376641384 citedByCount "2" @default.
- W4376641384 countsByYear W43766413842023 @default.
- W4376641384 crossrefType "journal-article" @default.
- W4376641384 hasAuthorship W4376641384A5007345070 @default.
- W4376641384 hasAuthorship W4376641384A5060083195 @default.
- W4376641384 hasAuthorship W4376641384A5087923582 @default.
- W4376641384 hasBestOaLocation W43766413841 @default.
- W4376641384 hasConcept C126322002 @default.
- W4376641384 hasConcept C2776232967 @default.
- W4376641384 hasConcept C2776256026 @default.
- W4376641384 hasConcept C2779220645 @default.
- W4376641384 hasConcept C2779422266 @default.
- W4376641384 hasConcept C2779750558 @default.
- W4376641384 hasConcept C2993493390 @default.
- W4376641384 hasConcept C71924100 @default.
- W4376641384 hasConceptScore W4376641384C126322002 @default.
- W4376641384 hasConceptScore W4376641384C2776232967 @default.
- W4376641384 hasConceptScore W4376641384C2776256026 @default.
- W4376641384 hasConceptScore W4376641384C2779220645 @default.
- W4376641384 hasConceptScore W4376641384C2779422266 @default.
- W4376641384 hasConceptScore W4376641384C2779750558 @default.
- W4376641384 hasConceptScore W4376641384C2993493390 @default.
- W4376641384 hasConceptScore W4376641384C71924100 @default.
- W4376641384 hasLocation W43766413841 @default.
- W4376641384 hasLocation W43766413842 @default.
- W4376641384 hasOpenAccess W4376641384 @default.
- W4376641384 hasPrimaryLocation W43766413841 @default.
- W4376641384 hasRelatedWork W2531312194 @default.
- W4376641384 hasRelatedWork W2532503897 @default.
- W4376641384 hasRelatedWork W2747759007 @default.
- W4376641384 hasRelatedWork W2764093873 @default.
- W4376641384 hasRelatedWork W2767757381 @default.
- W4376641384 hasRelatedWork W2799723181 @default.
- W4376641384 hasRelatedWork W2947792078 @default.
- W4376641384 hasRelatedWork W2981771308 @default.
- W4376641384 hasRelatedWork W2987457019 @default.
- W4376641384 hasRelatedWork W2993351595 @default.
- W4376641384 hasVolume "187" @default.
- W4376641384 isParatext "false" @default.
- W4376641384 isRetracted "false" @default.
- W4376641384 workType "article" @default.